It’s been a crucial week for Hologic, Inc. (NASDAQ:HOLX); here’s what analysts have to say.

Hologic, Inc. (NASDAQ:HOLX) Logo
Investors sentiment increased to 1.22 in 2019 Q2. Its up 0.36, from 0.86 in 2019Q1. It is positive, as 25 investors sold Hologic, Inc. shares while 123 reduced holdings. 61 funds opened positions while 119 raised stakes. 249.45 million shares or 1.69% less from 253.74 million shares in 2019Q1 were reported.
Bb&T Securities Limited Liability holds 165,476 shares. Moody Bank Division reported 28,269 shares. Nomura Asset Management has 48,801 shares for 0.02% of their portfolio. Quantbot Technology Lp holds 0.01% or 1,559 shares. 11.30M were accumulated by State Street Corp. Alliancebernstein Lp reported 442,950 shares or 0.01% of all its holdings. The Florida-based Raymond James Associates has invested 0.01% in Hologic, Inc. (NASDAQ:HOLX). Majedie Asset Mngmt Ltd invested in 72,535 shares. 289,318 were reported by Renaissance Tech. Wedge Cap Mngmt L Limited Partnership Nc owns 703,931 shares for 0.39% of their portfolio. Choate Invest Advisors has invested 0.08% of its portfolio in Hologic, Inc. (NASDAQ:HOLX). Gsa Capital Partners Ltd Liability Partnership accumulated 35,900 shares. Glenmede Na holds 4,359 shares or 0% of its portfolio. Endurance Wealth Management Incorporated holds 0.06% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 8,384 shares. American Int Gp Inc holds 96,106 shares.

Hologic, Inc. (NASDAQ:HOLX) Ratings Coverage

Among 2 analysts covering Hologic (NASDAQ:HOLX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Hologic has $52 highest and $4800 lowest target. $50’s average target is 0.56% above currents $49.72 stock price. Hologic had 4 analyst reports since April 4, 2019 according to SRatingsIntel. The stock of Hologic, Inc. (NASDAQ:HOLX) earned “Buy” rating by Needham on Friday, June 21. The firm has “Hold” rating given on Monday, August 5 by Stifel Nicolaus. Below is a list of Hologic, Inc. (NASDAQ:HOLX) latest ratings and price target changes.

05/08/2019 Broker: Stifel Nicolaus Rating: Hold Old Target: $43.0000 New Target: $48.0000 Maintain
21/06/2019 Broker: Needham Rating: Buy New Target: $52 Maintain
26/04/2019 Broker: BidaskScore Rating: Hold Upgrade
04/04/2019 Broker: BidaskScore Rating: Buy Downgrade

The stock decreased 0.20% or $0.1 during the last trading session, reaching $49.72. About 1.00 million shares traded. Hologic, Inc. (NASDAQ:HOLX) has risen 19.41% since September 13, 2018 and is uptrending. It has outperformed by 19.41% the S&P500.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company has market cap of $13.29 billion. It operates through four divisions: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It currently has negative earnings. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test.

More notable recent Hologic, Inc. (NASDAQ:HOLX) news were published by: which released: “Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings? – Nasdaq” on July 24, 2019, also with their article: “The 10 Biggest Winners From Second-Quarter Earnings –” published on August 26, 2019, published: “First Week of October 18th Options Trading For Hologic (HOLX) – Nasdaq” on August 23, 2019. More interesting news about Hologic, Inc. (NASDAQ:HOLX) were released by: and their article: “Here’s Why You Should Invest in Hologic (HOLX) Stock Now – Nasdaq” published on September 02, 2019 as well as‘s news article titled: “RBC Capital: 5 New Stocks Hedge Funds Snapped Up In Q2 – Nasdaq” with publication date: August 26, 2019.

Hologic, Inc. (NASDAQ:HOLX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.